Skip to main content
SpringerLink
Log in

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: To assess the feasibility of administering ZD9331, a thymidylate synthase (TS) inhibitor that does not undergo polyglutamation and has broad antitumor activity, in combination with docetaxel in patients with advanced solid malignancies. The study also sought to determine the principal toxicities of the regimen and recommend appropriate doses for phase II studies, characterize the pharmacokinetics of the agents, evaluate the possibility of major drug-drug interactions, and seek preliminary evidence of anti-cancer activity. Patients and methods: Patients with advanced solid malignancies were treated with escalating doses of docetaxel as a 60-minute intravenous (IV) infusion followed 30 minutes later by ZD9331 as a 30-minute IV infusion every 3 weeks. At least three patients were treated at each dose level, and the maximum tolerated dose level was defined as the highest dose level that was not associated with an unacceptably high incidence of severe toxicity. The pharmacokinetics of both ZD9331 and docetaxel were also characterized. Results: Nineteen patients were treated with 71 cycles of ZD9331 and docetaxel (ZD9331/docetaxel) at dose levels that encompassed dosing iterations of ZD9331 ranging from 65 to 260 mg/m2 and docetaxel doses in the range of 50 to 75 mg/m2. Neutropenia was the principal toxicity of the ZD9331/docetaxel regimen. Since five of six patients treated at the ZD9331/docetaxel dose-level of 260/60 mg/m2 had grade 4 neutropenia that was brief and uncomplicated in the first course, a rigorous exploration of higher dose levels was not undertaken. Nonhematologic toxicities, consisting of malaise, diarrhea, rash, nausea, and vomiting, were also observed, but these effects were rarely severe. No major antitumor responses were observed. The pharmacokinetics of both ZD9331 and docetaxel were similar to those reported in previous studies of each agent administered alone, suggesting the lack of major drug-drug interactions. Conclusion: The combination regimen, consisting of ZD9331 and docetaxel, is feasible and well tolerated at single-agent doses that are clinically-relevant. This ZD9331/docetaxel regimen does not appear to be associated with either major pharmacokinetic or toxicologic drug-drug interactions. A ZD9331/docetaxel dose level of 260/60 mg/m2 is recommended as an initial dose level in disease-directed studies of the regimen, with further dose escalation of docetaxel to 75 mg/m2 if the initial treatment is well tolerated. Further studies with this regimen are warranted in tumor types that have demonstrated sensitivity to both agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6: 871–881, 1995

    Google Scholar 

  2. Jackman AL, Judson IR: The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest Drugs 5: 719–736, 1996

    Google Scholar 

  3. Rustum YM, Harstrick A, Cao S, et al.: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1987; 15: 389–400, 1997

    Google Scholar 

  4. Touroutoglou N, Pazdur R: Thymidylate synthase inhibitors. Clin Cancer Res 2: 227–243, 1996

    Google Scholar 

  5. Rhee MS, WangY, Nair MG, Galivan J: Acquisition of resistance to antifolates caused by enhaced ?-glutamyl hydrolase activity. Cancer Res 53: 2227–2230, 1993

    Google Scholar 

  6. Pizzorno G, Mini E, Coronnello M, et al.: Impaired polyglutamation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high dose treatment with this drug. Cancer Res 48: 2149–2155, 1988

    Google Scholar 

  7. McCloskey DE, McGuire JJ, Russell CA, et al.: Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem266: 6181–6187, 1991

    Google Scholar 

  8. Jackman AL, Kelland LR, Kimbell, R, et al.: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex), in one mouse and three human cell lines. Br J Cancer 71: 914–924, 1995

    Google Scholar 

  9. Li WW, Waltham M, Tong W, Schweitzer BI, Bertino JR: Increased activity of ?-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. In: Ayling JE, Nair MG, Baugh CM (eds) Chemistry and Biology of Pieridines and Folates, Advances in Experimental Medicine and Biology. Vol. 338, New York: Plenum 1993, pp. 635–638

    Google Scholar 

  10. Wardleworth JM, Boyle JF, Jackman AL, et al.: ZD9331, the design and synthesis of a novel non-polyglutamatable TS inhibitor. Ann Oncol 5(Suppl 5): 247, 1994

    Google Scholar 

  11. Jackman AL, Kimbell R, Brown M, et al.: The antitumor activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 370: 185–188, 1994

    Google Scholar 

  12. Boyle FT, Stephens TC, Averbuch SD, Jackman AL.: ZD9331: Preclinical and clinical studies. In Jackman AL (ed) Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa NJ: Humana Press Inc., pp. 243–260

  13. Aherne GW, Hardcastle A., Ward E, et al.: Pharmacokinetic/ pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. Clin Can Res 7: 2923–2930, 2001

    Google Scholar 

  14. Jackman AL, Kimbell R, Aherne GW, et al.: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Can Res 3: 911–921, 1997

    Google Scholar 

  15. Jackson RC, Jackman AL, Calvert AH: Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells. Biochem Pharmacol 32: 3783–3790, 1983

    Google Scholar 

  16. Jackman AL, Taylor GA, Gibson W, et al.: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitroand in vivo: new agent for clinical study. Cancer J Res 51: 5579–5586, 1991

    Google Scholar 

  17. Jackman AL, Farrugia DC, Gibson W, et al.: ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur. J Cancer 31A: 1277–1282, 1995

    Google Scholar 

  18. Jackman AL, Judson IR. The new generation of thymidylate synthase inhibitors in clinical study: Oncologic, endocrine and metabolic. Exp Opin Investig Drugs 5: 719–736, 1996

    Google Scholar 

  19. Jackman AL, Kelland LR, Kimbell R, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71914–71924, 1995

  20. Jackman AL, Taylor GA, Calvert AH, et al. Modulation of antimetabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitors, CB3717. Biochem Pharmacol 33: 3269–3275, 1984

    Google Scholar 

  21. Clarke SJ, Jackman AL, Judson IR: The history of the development and clinical use of CB3717 and ICI D1694. Adv Exp Med Biol 339: 277–287, 1993

    Google Scholar 

  22. Stephens TC, Smith MN, McCloskey ML: ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: In vivoantitumour efficacy and toxicity to normal murine tissues. Proc Am Assoc Cancer Res35: 305, 1994 (abstract)

    Google Scholar 

  23. Goh BC, Ratain M, Bertucci D, et al.: Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Onc 19: 1476–1484, 2001

    Google Scholar 

  24. Diab S, Britten C, Eckhardt G, et al.: Phase I and pharmacokinetic study of the nonpolyglutaminate thymidylate synthase inhibitor ZD9331 on a 30 minute infusion every 3 week schedule. Proc Am Soc Clin Oncol 17: 226, 1998, (abstract)

    Google Scholar 

  25. Rees C, Beale P, Trigo JM, et al.: Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clin Cancer Res 9: 2049–2055, 2003

    Google Scholar 

  26. Plummer R, Rees C, Hughes A, et al.: Phase I trial of ZD9331, a water-soluble, non-polyglutamatable thymidylate synthase inhibitor. Clin Cancer Res 9: 1313–1322, 2003

    Google Scholar 

  27. Ford HER, Mitchell F, Cunningham D, et al.: Patterns of elevation of plasma 2'deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 8: 103–109, 2002

    Google Scholar 

  28. Rader JS, Clarke-Pearson D, Moore M, et al.: A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecol Oncol 91: 318–325, 2003

    Google Scholar 

  29. Hainsworth J, Vergote I, Janssens J: A review of phase II studies of ZD9331 treatment for relapsed and refractory solid tumors. Anticancer Drugs 14(Suppl 1): S13–S19, 2003

    Google Scholar 

  30. Petruzelka L: Phase II multicenter trial of ZD9331 monotherapy as first-line treatment for gastric cancer. Anticancer Drugs 14(Suppl 1): S7–S12, 2003

    Google Scholar 

  31. Smith D, Gallagher N.: A phase II/III study comparing ZD9331 with gemcitabine in patients with pancreatic cancer. Eur J Cancer 39: 1377–1383, 2003

    Google Scholar 

  32. Rizzo JD, Villalona-Calero M, Garrison M, et al. A pharmacologic and metabolic study of docetaxel administered on a continuous weekly schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22: 162, 2003 (abstract)

    Google Scholar 

  33. Cortes JE: Pazdur R. Docetaxel. J Clin Oncol 13: 2643–2655, 1995

    Google Scholar 

  34. Bruno R, Vivier N, Veyrat-Follet C, et al.: Population pharmacokinetics and pharmacokinetic-pharmadynamic relationships for docetaxel. Invest New Drugs 19: 163–169, 2001

    Google Scholar 

  35. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36: 99–114, 1999

    Google Scholar 

  36. Sawyers MB, Ratain MJ, Bertucci D, et al: Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol 21: 1859–1865, 2003

    Google Scholar 

  37. de Jonge MJA, Glimelkius B, Verweij J, et al.: Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-Cancer Drugs 13: 645–643, 2004

    Google Scholar 

  38. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, et al.: Design of thymidylate synthase inhibitor using protein crystal structures: The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem36: 733–745, 1993

    Google Scholar 

  39. Walton MI, Mitchell F, Aherne GW, et al.: The renal effects of the water soluble non-folylpolyglutamate synthase dependent thymidylate synthase inhibitor, ZD9331, in mice. Br J Can 78: 1457–1463, 1998

    Google Scholar 

  40. Adachi II, Taguchi T: The clinical utility of docetaxel in adriamycin-resistant breast cancer. Breast Cancer 4: 273–279, 1997

    Google Scholar 

  41. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: AJapanese cooperative study. J Clin Oncol 5: 1649–1655, 1996

    Google Scholar 

  42. Theti D, Jackman AL: The role of a-folate receptor-mediated transport in the antiumor activity of antifolate drugs. Clin Cancer Res 10: 1080–1089, 2004

    Google Scholar 

  43. Tomassetti A, Mangiarotti F, Mazzi M, et al.: The variant hepatocyte nuclear factor 1 activates the P1 promotor of the human a-folate receptor gene in ovarian cancer. Cancer Res 63: 696–704, 2003

    Google Scholar 

  44. Leamon CP, Low PS: Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discovery Today 6: 44–51, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brooke Army Medical Center, San Antonio, TX, USA

    Garry H. Schwartz, Christopher B. Jones & Mitchell Garrison

  2. Institute for Drug Development, Cancer Therapy and Research Center, and The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Amita Patnaik, Chris Takimoto, Heather McCreery, Anthony W. Tolcher & Eric K. Rowinsky

  3. AstraZeneca Pharmaceuticals Inc., Wilmington, Delaware, USA

    Michael Skinner

Authors
  1. Garry H. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher B. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitchell Garrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amita Patnaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chris Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heather McCreery
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael Skinner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anthony W. Tolcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eric K. Rowinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, G.H., Jones, C.B., Garrison, M. et al. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Invest New Drugs 22, 437–448 (2004). https://doi.org/10.1023/B:DRUG.0000036686.86700.a9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000036686.86700.a9

Search

Navigation